GNQ Insilico Inc., a Toronto-based TechBio company integrating artificial intelligence, quantum computing, and genomics for drug discovery, has agreed to go public through a business combination with IB Acquisition Corp., a Nevada-based special purpose acquisition company, in a transaction that values GNQ at approximately $688 million (US$500 million), with additional consideration possible through revenue and share price earnout provisions.
Under the definitive agreement, IBAC will acquire all outstanding GNQ shares by way of a plan of arrangement under the Canada Business Corporations Act. The deal is expected to provide approximately US$15 million in proceeds to GNQ, comprising a private investment in public equity (PIPE) of up to US$10 million, cash held in IBAC's trust account, and up to US$2 million in bridge financing through convertible notes and warrants.
Founded by Rehan Huda, GNQ operates three proprietary platforms designed to accelerate drug discovery. Its drug assessment platform launched in the fourth quarter of 2025, with its drug simulation and digital twins platforms expected later in 2026.
GNQ's current executive team will lead the combined company post-closing, with a five-member board consisting of four GNQ designees and one independent IBAC sponsor designee.
“Partnering with IB Acquisition Corp. marks a pivotal moment for GNQ as we scale our three comprehensive AI-powered drug assessment, drug simulation and digital twins platform to transform pharmaceutical R&D and healthcare delivery,” GNQ founder, chairperson, and CEO Rehan Huda said in a press release. “Our platforms address critical inefficiencies across the healthcare value chain, enabling smarter investment decisions and accelerating drug development to deliver truly personalized medicine. This transaction provides the resources and public market visibility to expand our commercial partnerships and scale our solutions to serve pharmaceutical companies, investors and healthcare providers worldwide.”
“IB Acquisition Corp. was formed with the goal of identifying a compelling partner at the forefront of innovation, and we are excited to have found that in GNQ Insilico,” said IBAC CEO and chairman Al Lopez. “GNQ’s integration of genomics, artificial intelligence, and quantum computing represents a differentiated approach to addressing the significant challenges facing drug discovery and development. We believe GNQ is well-positioned to capture meaningful market share and have great confidence in the talented GNQ team.”
Cassels Brock & Blackwell LLP and Barnes & Thornburg LLP are serving as legal counsel to GNQ. Dentons Canada LLP and ArentFox Schiff LLP are serving as legal counsel to IBAC, with I-Bankers Securities, Inc. acting as financial and capital markets advisor.
The deal is expected to close in the third quarter of 2026, subject to customary closing conditions.
For comprehensive access to our database of all published deal information, subscribe to the CL+ platform.